- Home
- COUR vs AUPH Comparison
COUR vs AUPH Comparison
Compare COUR & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COUR
- AUPH
- Stock Information
- Founded
- COUR 2012
- AUPH 1993
- Country
- COUR United States
- AUPH Canada
- Employees
- COUR N/A
- AUPH N/A
- Industry
- COUR Computer Software: Prepackaged Software
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- COUR Technology
- AUPH Health Care
- Exchange
- COUR Nasdaq
- AUPH Nasdaq
- Market Cap
- COUR 1.8B
- AUPH 1.6B
- IPO Year
- COUR 2021
- AUPH 1999
- Fundamental
- Price
- COUR $8.50
- AUPH $15.56
- Analyst Decision
- COUR Buy
- AUPH Strong Buy
- Analyst Count
- COUR 11
- AUPH 3
- Target Price
- COUR $12.36
- AUPH $17.67
- AVG Volume (30 Days)
- COUR 3.0M
- AUPH 1.9M
- Earning Date
- COUR 10-23-2025
- AUPH 11-04-2025
- Dividend Yield
- COUR N/A
- AUPH N/A
- EPS Growth
- COUR N/A
- AUPH N/A
- EPS
- COUR N/A
- AUPH 0.55
- Revenue
- COUR $739,774,000.00
- AUPH $265,808,000.00
- Revenue This Year
- COUR $10.46
- AUPH $17.33
- Revenue Next Year
- COUR $6.00
- AUPH $14.31
- P/E Ratio
- COUR N/A
- AUPH $28.25
- Revenue Growth
- COUR 8.09
- AUPH 20.62
- 52 Week Low
- COUR $5.76
- AUPH $6.55
- 52 Week High
- COUR $13.56
- AUPH $16.20
- Technical
- Relative Strength Index (RSI)
- COUR 36.48
- AUPH 75.68
- Support Level
- COUR $8.26
- AUPH $13.34
- Resistance Level
- COUR $8.52
- AUPH $15.27
- Average True Range (ATR)
- COUR 0.30
- AUPH 0.81
- MACD
- COUR 0.02
- AUPH 0.32
- Stochastic Oscillator
- COUR 29.34
- AUPH 85.28
About COUR Coursera Inc.
Coursera Inc is an online learning platform that connects learners, educators, and institutions with the goal of providing educational content that is affordable, accessible, and relevant. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The company operates through three reporting segments: Consumer, Enterprise, and Degrees. The majority of revenue is generated from the Consumer segment. The consumer segment targets individual learners seeking to obtain hands-on learning, gain valuable job skills, receive professional-level certifications, and otherwise increase their knowledge to start or advance their careers.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.